Aethlon Medical Releases Shareholder Letter to Discuss Cancer Exosome Studies in The U.S.

Jun 15, 2010, 08:30 ET from Aethlon Medical, Inc.

SAN DIEGO, June 15 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that its Chairman and CEO, James A. Joyce has issued the following letter to shareholders.


Dear Shareholder:

Should you or a loved one become afflicted with cancer, tumors will release particles that kill off immune cells needed to combat cancer. We recently discovered our Hemopurifier® is effective in capturing these particles, known as exosomes.  Prior to this observation, a therapeutic strategy to directly inhibit or remove this immunosuppressive mechanism did not exist in cancer care.  

On May 4th of this year, we disclosed our intent to utilize relationships in India to initiate a human pilot study to clinically document the effect of removing tumor-secreted exosomes on the immune response of cancer patients. Since revealing our plan, we have received an overwhelming number of collaborative inquiries from leading cancer research centers worldwide. As a result, we reevaluated our clinical strategy and have decided to pursue our first opportunity to treat cancer in the United States. However, we will continue to monitor treatment opportunities in other regions. While there is no assurance of success, feedback from thought leaders in the oncology field indicates that we are positioned at the forefront of the emerging industry to address cancer related exosomes.   As you can imagine, we are thrilled to be able to leverage the same Hemopurifier® we actively advance in infectious disease as a cancer treatment candidate.   Regarding our infectious disease opportunities, please note that we have reached an agreement on the protocol of our upcoming Hepatitis-C virus (HCV) treatment program in India, which will be detailed in a forthcoming report.  I thank you for your continued support and belief in our endeavors, which has been instrumental in allowing us to advance our cancer discovery.  

Very truly yours,

James A. Joyce

Chairman, CEO

Certain of the statements in the above Shareholder Letter may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.  Such potential risks and uncertainties include, without limitation, the capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify disease conditions such as cancer, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.


James A. Joyce

Chairman, CEO

858.459.7800 x301

John P. Salvador

Director, Communications and Investor Relations

858.459.7800 x307

SOURCE Aethlon Medical, Inc.